Tuftsin-bearing liposomes in treatment of macrophage-based infections

Advanced Drug Delivery Reviews

Volumn 41, Issue 2, 2000, Pages 135-146

  Agrawal, Ajay K ^a   Gupta, C M ^b  

^a PolyMASC Pharmaceuticals plc   (United Kingdom)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Aspergillosis; Drug delivery system; Immunomodulation; Leishmaniasis; Liposome; Malaria; Mononuclear phagocyte system; Tuberculosis; Tuftsin

Indexed keywords

ANTIBIOTICS; BIOCHEMICAL ENGINEERING; CELLS; DISEASES; DRUG PRODUCTS; ENZYMES; GRAFTING (CHEMICAL); IMMUNOLOGY;

ASPERGILLOSIS; DRUG DELIVERY SYSTEM; IMMUNOMODULATION; LEISHMANIASIS; LIPOSOME; MACROPHAGE BASED INFECTIONS; MALARIA; MONONUCLEAR PHAGOCYTE SYSTEM; TUBERCULOSIS; TUFTSIN BEARING LIPOSOMES;

CONTROLLED DRUG DELIVERY;

AMINOSALICYLIC ACID; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; ANTIPROTOZOAL AGENT; CHLOROQUINE; ETHAMBUTOL; HAMYCIN; ISONIAZID; LIPOSOME; PENTAMIDINE ISETHIONATE; PYRAZINAMIDE; RIFAMPICIN; STIBOGLUCONATE SODIUM; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; TUFTSIN; UREA STIBAMINE;

ASPERGILLOSIS; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; LEISHMANIASIS; LIVER TOXICITY; MACROPHAGE ACTIVATION; MALARIA; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; TUBERCULOSIS;

EID: 0343446135     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00061-7     Document Type: Article

References (95)

1. Poznansky M.J., Juliano R.L. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev. 36:1984;277-336.
2. Green R., Widder K.J. Methods Enzymology. Drug and Enzyme Targeting. Vol. 149:1987;51-213 Academic Press, CA.
3. Ranade V.V. Drug delivery systems. 6. Transdermal drug delivery. J. Clin. Pharmacol. 31:1991;401-418.
4. R) liposomes. J. Liposome Res. 4:1994;1-25.
5. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 13:1995;527-537.
6. Francis G.E., Delgado C., Fisher D., Malik F., Agrawal A.K. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. J. Drug Target. 3:1996;321-340.
7. A.K. Agrawal, C.M. Gupta, Antibody-Bearing Liposomes as Chloroquine Vehicles in Treatment of Murine Malaria, in: G.E. Francis, C. Delgado (Eds.), Drug Targeting, Humana Press Inc., New Jersey, USA, 1999 (in press).
8. Ostro M.J. Liposomes Sci. Am. 256:1987;102-111.
9. Alving C.R. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today. 2:1986;101-107.
10. Ghosh P.C., Bachhawat B.K. Targeting of Liposomes To Hepatocytes. Wu G.Y., Wu C.H. Liver Diseases: Diagnosis and Therapy using Specific Receptor and Ligands. 1991;87-103 Marcel Dekker, New York.
11. Bakker-Woudenberg I.A., Storm G., Woodle M.C. Liposomes in the treatment of infections. J. Drug Target. 2:1994;363-371.
12. Lasic D.D. Recent developments in medical applications of liposomes; sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J. Control. Release. 48:1997;203-222.
13. Senior J. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3:1987;123-193.
14. Bradfield J.W.B. The Reticuloendothelial System and Blood Clearance. Davies S.S., Illum J.G., Tomilinson E. Microspheres and Drug Therapy, Pharmaceutical, Immunological and Medical Aspects. 1984;25 Elsevier, Amsterdam.
15. Patel H.M. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
16. Singhal A., Bali A., Jain R.K., Gupta C.M. Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers. FEBS Lett. 178:1984;109-113.
17. Gupta C.M., Puri A., Jain R.K., Bali A., Anand N. Protection of mice against Plasmodium berghei infection by a tuftsin derivative. FEBS Lett. 205:1986;351-354.
18. Bhakuni V., Gupta C.M. Interactions of tuftsin with bovine serum albumin. FEBS Lett. 205:1986;347-350.
19. Guru P.Y., Agrawal A.K., Singha U.K., Singhal A., Gupta C.M. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett. 245:1989;204-208.
20. Ahmad I., Agarwal A., Pal A., Guru P.Y., Bachhawat B.K., Gupta C.M. Tissue distribution and antileishmanial activity of liposomised Amphotericin-B in Balb/mice. J. Biosci. 14:1991;217-221.
21. Singh S.P., Chabra R., Srivastava V.M.L. Respiratory burst in peritoneal exudate cells in response to modified tuftsin. Experientia. 48:1992;994-996.
22. Owais M., Ahmed I., Krishnakumar K., Jain R.K., Bachhawat B.K., Gupta C.M. Tuftsin-bearing liposomes as drug vehicles in treatment of experimental aspergillosis. FEBS Lett. 326:1993;56-58.
23. Agarwal A., Kandpal H., Gupta H.P., Singh N.B., Gupta C.M. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 38:1994;588-593.
24. Najjar V.A. Biological effects of tuftsin and its analogs. Drugs Future. 12:1987;147-160.
25. Fridkin M., Najjar V.A. Tuftsin: its chemistry, biology, and clinical potential. Crit. Rev. Biochem. Mol. Biol. 24:1989;1-40.
26. Nishioka K., Hopfer R.L., el-Hagin T., Lopez-Berestein G. Prophylaxis of Candida albicans infection with tuftsin. J. Antimicrob. Chemother. 17:1986;361-363.
27. Pawan K., Ivanov B.B., Kabilan L., Rao D.N. Construction of a synthetic immunogen: use of the natural immunomodulator polytuftsin in malaria vaccines against RESA antigen of Plasmodium falciparum. Vaccine. 12:1994;819-824.
28. Khare S., Bhutani L.K., Rao D.N. Release of reactive nitrogen intermediates from the peripheral blood-derived monocytes/macrophages of leprosy patients stimulated in vitro by tuftsin. Leprosy Rev. 68:1997;16-24.
29. Bump N.J., Lee J., Wleklik M., Reichler J., Najjar V.A. Isolation and subunit composition of tuftsin receptor. Proc. Natl. Acad. Sci. USA. 83:1986;7187-7191.
30. Nishioka K., Obeyesekere N.U., McMurray J.S. Enhanced phagocytosis activity of cyclic analogs of tuftsin. Biochem. Pharmacol. 49:1995;735-738.
31. Gershonov E., Granoth R., Tzehoval E., Gaoni Y., Fridkin M. 1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs. J. Med. Chem. 39:1996;4833-4843.
32. Fridkin M., Gottlieb P. Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol. Cell. Biochem. 41:1981;73-97.
33. Gottlieb P., Beretz A., Fridkin M. Tuftsin analogs for probing its specific receptor site on phagocytic cells. Eur. J. Biochem. 125:1982;631-638.
34. Klebanoff S.J. Van Furth R. Mononuclear Phagocytes, Functional Aspects. 1980;1105 Martinus Nijhoff, Hague.
35. Hauser H., Pascher I., Pearson R.H., Sundell S. Preferred conformation and molecular packing of phosphatidylethanolamine and phosphatidylcholine. Biochim. Biophys. Acta. 650:1981;21-51.
36. Butler D., Maurice J., O'Brien C. Time to put malaria control on the global agenda. Nature. 386:1997;535-540.
37. Basco L.K., Tahar R., Ringwald P. Surveillance of antifolate-resistant malaria. Lancet. 352:(9125):1998;406.
38. Peters W. Drug resistance in malaria parasites of animals and man. Adv. Parasitol. 41:1998;1-62.
39. Martin S.K. Chloroquine-resistance Plasmodium falciparum and the MDR phenotype. Parasitol. Today. 9:1993;278-279.
40. Ridley R.G. Malaria: dissecting chloroquine resistance. Curr. Biol. 8:1998;R346-R349.
41. Peeters P.A., de Leest K., Eling W.M., Crommelin D.J. Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria. Pharm. Res. 6:1989;787-793.
42. Moll G.N., van den Eertwegh V., Tournois H., Roelofsen B., Op den Kamp J.A., van Deenen L.L. Growth inhibition of Plasmodium falciparum in in vitro cultures by selective action of tryptophan-N-formylated gramicidin incorporated in lipid vesicles. Biochim. Biophys. Acta. 1062:1991;206-210.
43. Green S., Fortier A., Dijkstra J., Madsen J., Swartz G., Einck L., Gubish E., Nacy C. Liposomal vaccines. Adv. Exp. Med. Biol. 383:1995;83-92.
44. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66:1998;2859-2865.
45. Heppner D.G., Gordon D.M., Gross M., Wellde B., Leitner W., Krzych U., Schneider I., Wirtz R.A., Richards R. L, Trofa A., Hall T., Sadoff J.C., Boerger P., Alving C.R., Sylvester D.R., Porter T.G., Ballou W.R. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174:1996;361-366.
46. Postma N.S., Hermsen C.C., Zuidema J., Eling W.M. Plasmodium vinckei: optimization of desferrioxamine B delivery in the treatment of murine malaria. Exp. Parasitol. 89:1998;323-330.
47. Alving C.R. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann. New York Acad. Sci. 754:1995;143-152.
48. Ling I.T., Ogun S.A., Momin P., Richards R.L., Garcon N., Cohen J., Ballou W.R., Holder A.A. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine. 15:1997;1562-1567.
49. Singhal A., Bali A., Gupta C.M. Antibody- mediated targeting of liposomes to erythrocytes in whole blood. Biochim. Biophys. Acta. 880:1986;72-77.
50. Singhal A., Gupta C.M. Antibody-mediated targeting of liposomes to red cells in vivo. FEBS Lett. 201:1986;321-326.
51. Agrawal A.K., Singhal A., Gupta C.M. Functional drug targeting to erythrocytes in vivo using antibody-bearing liposomes as drug vehicles. Biochem. Biophys. Res. Commun. 148:1987;357-361.
52. Chandra S., Agrawal A.K., Gupta C.M. Chloroquine delivery to erythrocytes in Plasmodiumberghei-infected mice using antibody-bearing liposomes as drug vehicles. J. Biosci. 16:1991;137-144.
53. Owais M., Varshney G.C., Choudhury A., Chandra S., Gupta C.M. Chloroquine encapsulated in malaria-infected erythrocytes-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice. Antimicrob. Agents Chemother. 39:1995;180-184.
54. Ockenhouse C.F., Shear H. L. Oxidative killing of the intraerythrocytic malaria parasite Plasmodium yoelii by activated macrophages. J. Immunol. 132:1984;424-431.
55. Clayton C.E. Tropical Diseases Research Series:1. The Role of the Spleen in the Immunology of Parasitic Disease. 1979;97-119 Schwabe, Basel.
56. Kshirsagar N.A., Gokhale P.C., Pandya S.K. Liposomes as drug delivery system in leishmaniasis. J. Assoc. Physicians India. 43:1995;46-48.
57. Banerjee G., Medda S., Basu M.K. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrob. Agents Chemother. 42:1998;348-351.
58. Coukell A.J., Brogden R.N. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. 55:1998;585-612.
59. Carter K.C., Dolan T.F., Alexander J., Baillie A.J., McColgan C. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 41:1989;87-91.
60. Banerjee G., Bhaduri A.N., Basu M.K. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochem. Med. Metabol. Biol. 53:1994;1-7.
61. Banerjee G., Nandi G., Mahato S.B., Pakrashi A., Basu M.K. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J. Antimicrob. Chemother. 38:1996;145-150.
62. Bryceson A.D.M. The Leishmaniasis in Biology and Medicine. Therapy in Man. 1987;Academic Press, London.
63. Berman J.D., Hanson W.L., Chapman W.L., Alving C.R., Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30:1986;847-851.
64. Stevens D.A. Therapy for opportunistic fungal infections: past, present and future. Indian J. Cancer. 32:1995;1-9.
65. Andriole V.T. Current and future therapy of invasive fungal infections. Curr. Clin. Top. Infect. Des. 18:1998;19-36.
66. Hay R.J. Antifungal drugs on the horizon. J. Am. Acad. Dermatol. 31:1994;S82-S86.
67. Deepe G.S, Jr. Arora D.K., Ajello L., Mukerji K.G. Handbook of Applied Mycology. Vol. 2:1991;205-241 Marcel Dekker Inc.
68. Abu-Salah K.M. Amphotericin B: an update. Br. J. Biomed. Sci. 53:1996;122-133.
69. Hoeprich P.D., Merry J.M., Gunther R., Franti C.E. Entry of five antifungal agents into the ovine lung. Antomicrob. Agents Chemother. 31:1987;1234-1237.
70. al-Arishi H., Frayha H.H., Kalloghlian A., alAlaiyan S. Liposomal amphotericin B in neonates with invasive candidiasis. Am. J. Perinatol. 14:1997;573-576.
71. Walsh T.J., Yeldandi V., McEvoy M., Gonzalez C., Chanock S., Freifeld A., Seibel N.I., Whitcomb P.O., Jarosinski P., Boswell G., Bekersky I., Alak A., Buell D., Barret J., Wilson W. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob. Agents Chemother. 42:1998;2391-2398.
72. Patel R. Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin. Proc. 73:1998;1205-1225.
73. Coukell A.J., Brogden R.N. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. 55:1998;585-612.
74. Welsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., Pappas P., Seibel N., Greenberg R.N., Dummer S., Schuster M., Holcenberg J.S. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia National Institute of Allergy and Infectious Diseases Mycoses Study Group. New Engl. J. Med. 340:1999;764-771.
75. Lambros M.P., Bourne D.W., Abbas S.A., Johnson D.L. Disposition of aerosolized liposomal amphotericin B. J. Pharm. Sci. 86:1997;1066-1069.
76. Lopez-Berestein G., Mehta R., Hoper R.L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E.M., Juliano R.L. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. J. Infect. Dis. 147:1983;939-945.
77. Szoka F.C. Jr., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 31:1987;421-429.
78. Jullien S., Contrepois A., Sligh J.E., Domart Y., Yeni P., Brajtburg J., Medoff G., Bolard J. Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob. Agents Chemother. 33:1989;345-349.
79. Jullien S., Brajtburg J., Bolard J. Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. Biochim. Biophys. Acta. 1021:1990;39-45.
80. Noordeen S.K., Godal T. Introduction. Br. Med. Bull. 44:1988;523-527.
81. Weiss R. On the track of 'killer' TB. Science. 255:1992;148-150.
82. Tuberculosis control and research strategies for the 1990s, Memorandum from a WHO meeting, Bull. WHO 70 (1992) 17.
83. Girling D.J. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle. 59:1978;13-32.
84. Zierski M., Bek E. Side effects of drug regimens used in short course chemotherapy of pulmonary tuberculosis: a controlled study. Tubercle. 61:1980;41-49.
85. Raleigh J.W. Rifampin in treatment of advanced pulmonary tuberculosis. Am. Rev. Respir. Dis. 105:1972;397-407.
86. Draper P. Mycobacterial Inhibition of Intracellular Killing. O'Grady F., Smith H. Microbial Perturbarion of Host Defences. 1981;143-164 Academic Press, London.
87. Mitchison D.A., Ellard G.A., Grosset J. New antibacterial drugs for the treatment of mycobacterial disease in men. Br. Med. Bull. 44:1988;757-774.
88. Bermudez L.E. Use of liposome preparation to treat mycobacterial infections. Immunobiology. 191:1994;578-583.
89. Deol P., Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta. 1334:1997;161-172.
90. Ozeki Y., Kaneda K., Fujiwara N., Morimoto M., Oka S., Yano I. In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6′-dimycolate). Infect. Immun. 65:1997;1793-1799.
91. Deol P., Khuller G.K., Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41:1997;1211-1214.
92. Konno K., Dizumi K., Anji F., Yamaguchi J., Oka S. Mode of action of infampin on mycobacteria. 1. Electron microscopic study of the effect of rifampin on Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 107:1973;1002-1005.
93. Raleigh J.W. Kubica G.P., Wayne L.G. The Mycobacteria, A Source Book. Chemotherapy of Tuberculosis. Vol. 15:1984;1007-1020 Marcel Dekker Inc, New York. Microbiology series, Library of Congress cataloguing in publication data.
94. Pabst M.J., Gross J.M., Brozna J.P., Goren M.B. Inhibition of macrophage priming by sulfatide from Mycobacterium tuberculosis. J. Immunol. 140:1988;634-640.
95. Orozco L.C., Forero M., Wasserman M., Ahumada J.J. Distribution of lip in tuberculous mice. Tubercle. 71:1990;209-214.